Lipid Innovation Center manufactures first GMP PhytoChol batch

Evonik manufactured the first GMP-quality batch of PhytoChol lipid cholesterol at its new Lipid Innovation Center in Lafayette, Indiana, establishing initial production at a U.S. facility for pharmaceutical lipids used in lipid-nanoparticle drug-delivery systems.

Evonik said the first batch was produced at its Tippecanoe-site Lipid Innovation Center, a flexible facility for multiple lipid chemistries, manufacturing processes, and products. The company says full capacity is scheduled to come online by mid-2027 and that the U.S. government-supported center is intended to strengthen domestic supply of drug-delivery inputs for advanced therapies.

Headline metrics

First product	PhytoChol	A non-animal-derived cholesterol and excipient for lipid nanoparticles
Production milestone	First GMP-quality batch	Manufactured at Evonik's Tippecanoe facility in Lafayette, Indiana
Full-capacity target	Mid-2027	A company projection; the first batch is not evidence of full capacity

Highlights

Domestic pharmaceutical supplyThe U.S. facility produces pharmaceutical lipids used to enable advanced therapies, including mRNA and gene-delivery applications.
Flexible production platformLINC is designed to support multiple lipid classes, manufacturing processes, and products.

Resources

Evonik press releaseevonik.com
Evonik PhytoChol product pageevonik.com